PDF | On May 1, , WERNER BUSTAMANTE E and others published Osteocondrodistrofía deformante (enfermedad de Morquio). PDF | REsuMEN La enfermedad de Morquio A o Mucopolisacaridosis IV A es un trastorno de depósito lisosomal pro-ducida por alteración en. Request PDF on ResearchGate | On Aug 1, , Juan Politei and others published Enfermedad de Morquio (mucopolisacaridosis IV-A): aspectos clínicos, .
|Published (Last):||8 April 2009|
|PDF File Size:||14.12 Mb|
|ePub File Size:||13.95 Mb|
|Price:||Free* [*Free Regsitration Required]|
There was a dose-dependent clearance of storage material observed in brain, and blood keratan sulfate was reduced to nearly normal levels. The mean birth lengths of boys and girls were Patients with Morquio A are usually evaluated during the second year of life for unique skeletal features including knock-knee, growth retardation, laxity of joints and abnormal gait with a tendency to fall in addition to kyphosis, protrusion of the chest and prominent forehead Figures 1 — 3.
By 12 months old, vacuolar change was observed in glomeruli and heart valves. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice. Enhancement of drug delivery: Trafficking of lysosomal enzymes. Incidence of the mucopolysaccharidoses in western Australia.
These findings, coupled with previously reported mutations, brought the total of different mutations to 41 among independent families with Morquio syndrome. In the latter, the Institute for the Study of Inborn Errors of Metabolismhas played a significant role in the design and evaluation of adenoassociated virus-derived vectors, towards the development of a gene therapy strategy for Morquio A. Join BioMarin for helpful Morquio A information, tools, and support.
You may report side effects to BioMarin Pharmaceutical Inc. Although this is not a complete remission in bone pathology, this finding demonstrates the importance of early treatment. The documents contained in this web site are presented for information purposes only.
Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs. Modulation of plasmid DNA methylation and expression in Zebrafish embryons. Identification of a common mutation in mucopolysaccharidosis IVA: The patients ranged in age from 5 to 26 mogquio.
Keratan sulfate accumulates in various tissues inclusive of cartilage, the nucleus pulposus of the intervertebral disk and cornea. The authors used a 6-minute walk test and a 3-minute stair climb test as well as measuring respiratory evaluation by forced vital capacity FVC and maximum voluntary ventilation MVV. Eukaryotic promoters induced similar expression levels than those observed with viral promoter. Morquio A patients are mainly characterized by bone, heart and lung manifestations.
Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Various cells retrovirally transduced with N-acetylgalactosoaminesulfate sulfatase correct Morquio skin fibroblasts in vitro.
Enfermedad de Morquio A: Conclusiones
Europe gives gene therapy the green light. Growth charts for patients affected with Morquio A disease. If you have acute febrile or respiratory illness at the time of VIMIZIM infusion you may be at higher risk of life-threatening complications from hypersensitivity reactions.
Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. The primary efficacy measure was a 6-minute walk test distance.
Orphanet: Mucopolisacaridosis tipo 4 Morquio enfermedad de
Dd presentation of Morquio disease type A. These alternative promoters may help avoid the gene silencing associated with the CMV promoter [ 97 ]. Delivery of therapeutic agents to the bone.
Clinical manifestation and natural course of Morquio A disease. In spite of unique clinical features including laxity of joints and normal intelligence, delay of diagnosis often happens because of ignorance of this rare disorder and false negative results of urine total GAG assay. Log in Sign up. Neufeld E, Morqhio J.
Expert Opin Ther Pat. Errores Innatos del Metabolismo.